Seeking Alpha

Oncothyreon (ONTY +10.3%) spikes higher after Wedbush lifts its PT to $31 from $15 (implies a...

Oncothyreon (ONTY +10.3%) spikes higher after Wedbush lifts its PT to $31 from $15 (implies a 300%+ gain), and argues shares have a "highly asymmetric" risk-reward going into the expected Q1 2012 release of Phase III trial data for its Stimuvax cancer vaccine. (previously)
Comments (3)
  • John Rayhall
    , contributor
    Comments (92) | Send Message
     
    I'm seeing it at 4.14 down 7.38% unless I'm crazy?
    16 Nov 2011, 02:04 PM Reply Like
  • SA Editor Eric Jhonsa
    , contributor
    Comments (882) | Send Message
     
    Sorry, put the wrong ticker in. It's ONTY, now fixed.
    16 Nov 2011, 02:05 PM Reply Like
  • John Rayhall
    , contributor
    Comments (92) | Send Message
     
    Oh thanks :)
    16 Nov 2011, 02:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs